MONOCLONAL ANTIBODY FOR SURFACE ANTIGEN SPERM, AN ANTIGEN DETECTED BY SUCH ANTIBODY AND COMPRISING ITS VACCINE AND SPERMICIDE

摘要

1. A monoclonal antibody S19 expressed by the hybridoma deposit accessible under Access No. ATCC HB 12144, specific to a sperm surface glycoprotein SAGA-1. 2. A purified preparation of a sperm surface SAGA-1glycoprotein bound by the monoclonal antibody of Claim 1. 3. A contraceptive vaccine, comprising an amount of the sperm surface glycoprotein of Claim 2 in an amount effective to induce production of antibodies thereto when administered to a female mammal, in a pharmaceutically acceptable carrier. 4. The vaccine of Claim 3, wherein said glycoprotein is present in sufficient amounts such that, on completion of a vaccination protocol, said female mammal exhibits an antibody titer sufficiently high to provide at least 95 percent fertility inhibition. 5. A method for determining the antibody titer in a vaccination patient receiving the vaccine of Claim 3, comprising mixing a sample received from said vaccination patient with bound glycoprotein SAGA-1, bound on a solid matrix, and detecting binding between the glycoprotein SAGA-1, bound on a solid vehicle, and antigens present in the sample, wherein complete binding of all said bound glycoprotein is indicative of an antibody titer in said sample sufficient to inhibit fertilization in said patient. 6. A spermicide, comprising as an active agent the monoclonal antibody of Claim 1, in a pharmaceutically acceptable carrier. 7. The spermicide of Claim 6, wherein said spermicide comprises a concentration of monoclonal antibodies sufficient such that one dose of said spermicide effectively binds 100 percent of all sperm cells present in an ejaculate. 8. The spermicide of Claim 7, wherein said spermicide is prepared in the form of liposomes. 9. The spermicide of Claim 8, wherein said liposomes are non-phospholipid positively charged liposomes. 10. A method for determining the antibody titer in a vaccination patient receiving the vaccine of Claim 3, comprising mixing a sample received from said vaccination patient with glycoprotein SAGA-1 and measuring an amount of antibody in said sample, which is bound to the with glycoprotein SAGA-1.